Biogen Idec and Isis Pharmaceuticals target spinal muscular atrophy

Friday, January 6, 2012 09:58 AM

Biogen Idec and Isis Pharmaceuticals have entered into an exclusive, global option and partnership agreement under which they will jointly develop and commercialize ISIS-SMNRx, an antisense investigational drug that treats spinal muscular atrophy (SMA) by compensating for the underlying genetic defect that causes the disease.

The agreement awards Isis an upfront payment of $29 million, with the possibility to receive up to $45 million in milestone payments. While Isis will be responsible for global development of ISIS-SMNRx through phase II/III trials, Biogen Idec has the option to license ISIS-SMNRx until a successful phase II/III trial is completed. If Biogen Idec exercises its option, it will assume global development, regulatory, and commercialization responsibilities.

"SMA is a heartbreaking disease -- it can kill children before their second birthday and there are currently no therapies to treat the disease," said George A. Scangos, Ph.D., CEO of Biogen Idec. “Isis's antisense compound has the potential to be a highly effective, first-to-market therapy for this deadly disease.”

Isis initiated the first phase I clinic study evaluating ISIS-SMNRx in children with SMA in December 2011. Isis plans to follow this study with a phase I multiple-dose study.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs